Completed PHASE3 INTERVENTIONAL 2-arm NCT01766076

Atorvastatin for HAART Suboptimal Responders

Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial

Sponsor: Makerere University

Conditions Acquired Immune Deficiency Syndrome Virus

Interventions Placebo atorvastatin, Lipitor®

Updated 7 times since 2017 Last updated: May 20, 2015 Started: Jan 31, 2013 Primary completion: Feb 28, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acquired Immune Deficiency Syndrome Virus and is currently completed. Makerere University leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Makerere University
Vaccine and Gene Therapy Institute, Florida

Data source: Makerere University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.